18F-FDG silicon photomultiplier PET/CT: A pilot study comparing semi-quantitative measurements with standard PET/CT
Authors:
Open Access
- 5 June 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (6) , e0178936
Abstract
To evaluate if the new Discovery Molecular Insights (DMI) PET/CT scanner provides equivalent results compared to the standard of care PET/CT scanners (GE Discovery 600 or GE Discovery 690) used in our clinic and to explore any possible differences in semi-quantitative measurements. The local Institutional Review Board approved the protocol and written informed consent was obtained from each patient. Between September and November 2016, 50 patients underwent a single 18F-FDG injection and two scans: the clinical standard PET/CT followed immediately by the DMI PET/CT scan. We measured SUVmax and SUVmean of different background organs and up to four lesions per patient from data acquired using both scanners. DMI PET/CT identified all the 107 lesions detected by standard PET/CT scanners, as well as additional 37 areas of focal increased 18F-FDG uptake. The SUVmax values for all 107 lesions ranged 1.2 to 14.6 (mean ± SD: 2.8 ± 2.8), higher on DMI PET/CT compared with standard of care PET/CT. The mean lesion:aortic arch SUVmax ratio and mean lesion:liver SUVmax ratio were 0.2–15.2 (mean ± SD: 3.2 ± 2.6) and 0.2–8.5 (mean ± SD: 1.9 ± 1.4) respectively, higher on DMI PET/CT than standard PET/CT. These differences were statistically significant (P value < 0.0001) and not correlated to the delay in acquisition of DMI PET data (P < 0.0001). Our study shows high performance of the new DMI PET/CT scanner. This may have a significant role in diagnosing and staging disease, as well as for assessing and monitoring responses to therapies.Keywords
This publication has 20 references indexed in Scilit:
- Review of functional/anatomical imaging in oncologyNuclear Medicine Communications, 2012
- Variations in PET/CT Methodology for Oncologic Imaging at U.S. Academic Medical Centers: An Imaging Response Assessment Team SurveyJournal of Nuclear Medicine, 2011
- 18F-FDG PET/CT Imaging In OncologyAnnals of Saudi Medicine, 2011
- The standardized uptake value for F‐18 fluorodeoxyglucose is a sensitive predictive biomarker for cervical cancer treatment response and survivalCancer, 2007
- Positron Emission Tomography As an Imaging BiomarkerJournal of Clinical Oncology, 2006
- 18F-FDG PET as a candidate for "qualified biomarker": functional assessment of treatment response in oncology.2006
- Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug DevelopmentClinical Cancer Research, 2005
- Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients.2004
- SUV varies with time after injection in (18)F-FDG PET of breast cancer: characterization and method to adjust for time differences.2003
- Optimizing Imaging Time for Improved Performance in Oncology PET StudiesMolecular Imaging and Biology, 2002